Guangzhou Tonghui Pharmaceutical Co., Ltd.

Primary objective: This study uses rupatadine fumarate tablets developed by Guangzhou Tonghui Pharmaceutical Co., Ltd. (manufacturer: Hubei Weisen Pharmaceutical Co., Ltd., specification: 10 mg) as the test preparation and rupatadine fumarate tablets (trade name: Rupafin, specification: 10 mg), a non-imported original drug of the original research unit Laboratorios ERN, S.A., as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation under fasting or postprandial conditions. Secondary objective: Observe the safety of the test preparation and the reference preparation in healthy subjects.